3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Carcinoma
4
Squamous Cell Carcinoma of Head and Neck
3
Mouth Neoplasms
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Adenocarcinoma
3
Recurrence
2
Ovarian Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Laryngeal Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Carcinoma, Squamous Cell
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Skin Neoplasms
1
Sinonasal Squamous Cell Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Melanoma
1
Liposarcoma
1
Hemangiosarcoma
1
Interventions
durvalumab
2
Tretinoin
2
Paclitaxel
2
Carboplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Pemetrexed
1
MK 2206
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
cemiplimab
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled